Related Experiment Video
Updated: Sep 23, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children]
Elzbieta Zielińska1, Małgorzata Zubowska, Jerzy Bodalski
1Klinika Chorób Dzieci Uniwersytetu Medycznego w Łodzi.
Insights
Genetic variations in the GSTP1 gene increase the risk of ifosfamide-induced kidney damage in children. This finding highlights the importance of genetic screening for personalized ifosfamide (IF) treatment in pediatric oncology.
Area of Science:
- Pharmacogenetics
- Pediatric Nephrology
- Oncology
Context:
- Ifosfamide (IF) is a crucial chemotherapeutic agent used in treating various pediatric cancers.
- Nephrotoxicity is a significant dose-limiting side effect of ifosfamide therapy.
- Understanding genetic predispositions can optimize ifosfamide treatment protocols.
Purpose:
- To investigate the role of S-glutathione transferase (GSTM1, GSTP1, GSTT1) gene polymorphisms and urinary toxic metabolite concentrations as risk factors for ifosfamide-induced nephrotoxicity in children.
- To assess the correlation between specific genetic variations and the incidence/severity of kidney damage.
Summary:
- This study analyzed 37 children treated with ifosfamide, examining GST gene polymorphisms (GSTM1, GSTP1, GSTT1) and urinary metabolite levels.
- Utilizing PCR, PCR-RFLP, and 31P NMR, researchers found that the GSTP1 gene A-G codon 105 transition was significantly associated (p=0.01) with higher urinary excretion of toxic ifosfamide metabolites.
- This increased excretion correlated with cumulative drug dose, while age, sex, and GSTM1/GSTT1 deletions showed no significant impact.
Impact:
- Identifies GSTP1 gene mutations as a key genetic risk factor for ifosfamide nephrotoxicity in pediatric patients.
- Suggests potential for genetic screening to personalize ifosfamide dosing and mitigate renal complications.
- Provides valuable insights for developing safer chemotherapy regimens in pediatric oncology.
Abstract:
The aim of the study was an assessment of various risk factors for nephrotoxicity of ifosfamide (IF) in children taking into account the importance of the concentrations of toxic metabolites of the drug excreted with urine and the polymorphism of genes encoding S-glutathione transferases of mi, pi, and theta classes (GSTM1, GSTP1 and GSTT1). The study was carried out in 37 children aged 2-17 years (mean age 8.9 +/- 4.5 years) treated with IF in 3 g/m2 dose for various malignant diseases. For the assessment of the incidence of deletion of GSTM1 and GSTT1 genes PCR method was applied while in the case of GSTP1 gene the polymorphism of A-G codon 105 was detected by the PCR-RFLP method. Before and after each treatment cycle the cumulative ifosfamide dose was calculated and the biochemical indices of renal canalicular and glomerular function were assessed which were graduated according to extended WHO criteria. Additionally, nuclear magnetic resonance 31P NMR method was applied for calculation of the concentrations of ifosfamide nephrotoxic metabolites and of the unchanged drug excreted with urine. The analysis performed demonstrated that in children with GSTP1 gene A-G codon 105 transition, a statistically significantly (p = 0.01) higher urinary excretion of toxic ifosfamide metabolites occurred, that increased with the cumulative drug dose. The age, sex and deletions of GSTM1 and GSTT1 genes exerted no effect on the concentrations of the toxic metabolites excreted with urine. The results of the studies demonstrate that GSTP1 gene mutations are the genetic risk factor for nephrotoxic complications of ifosfamide use.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
